Integrative analyses demonstrated that the A52 gene signature aligns closely with a subset of human HCC lacking CTNNB1 mutations.<h4>Conclusion</h4>This study provides a critical genetic resource, facilitating more precise preclinical modeling and therapeutic validation in HCC. This evidence concerns the gene CTNNB1 and hepatocellular carcinoma.